Petmed Express Inc (PETS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q1 FY2027, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PETS SEC filings page.
Petmed Express Inc (PETS) reported $168.9M in revenue over the twelve months to Jun 30, 2026, down 20.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Operating-cost absorption now dominates, turning a previously cash-generative business into one with shrinking balance-sheet flexibility.
Over the latest two reported years, revenue contraction took sales to$179.0M from$227.0M , reducing the scale available to absorb operating costs. Gross margin stayed near30% , but operating margin reached-32.8% ; that gross-versus-operating margin split places the latest loss mainly below gross profit rather than in product-level economics.
Cash conversion reversed: operating cash flow was
Balance-sheet cushion narrowed as assets fell to
Financial Health Signals
Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Petmed Express Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Petmed Express Inc held $21.4M in cash, cash equivalents and investments at the end of fiscal year 2026, and its operations used $28.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Petmed Express Inc scores 28/100 among other emerging companies.
Petmed Express Inc had 21M shares outstanding at the end of fiscal year 2026, against 21M in fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Petmed Express Inc scores 71/100 among other emerging companies.
Not available for Petmed Express Inc, and counted as zero in the overall score.
Petmed Express Inc reported revenue of $179.0M in fiscal year 2026, against $227.0M in fiscal year 2025. Revenue Progress ranks emerging companies on the three-year path of that line, and Petmed Express Inc scores 20/100 among other emerging companies.
Not available for Petmed Express Inc, and counted as zero in the overall score.
Petmed Express Inc's cash, cash equivalents and investments came to $21.4M at the end of fiscal year 2026, against $52.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Petmed Express Inc scores 39/100 among other emerging companies.
Petmed Express Inc scores 0.27, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($35.8M) relative to total liabilities ($52.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Petmed Express Inc passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Petmed Express Inc reported a net loss of $57.3M while operations used $28.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Petmed Express Inc generated $41.0M in revenue in Q1 2027. This represents a decrease of 19.9% from the same quarter a year earlier. Against the prior quarter it is down 4.2%.
Petmed Express Inc's EBITDA was -$4.1M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 87.2% from the same quarter a year earlier. Against the prior quarter it is down 25.1%.
Petmed Express Inc reported -$6.1M in net income in Q1 2027. This represents an increase of 82.0% from the same quarter a year earlier. Against the prior quarter it is down 51.2%.
Petmed Express Inc earned -$0.28 per diluted share (EPS) in Q1 2027. This represents an increase of 83.0% from the same quarter a year earlier. Against the prior quarter it is down 47.4%.
Cash & Balance Sheet
Petmed Express Inc recorded an outflow of $8.3M in free cash flow in Q1 2027, representing a cash shortfall after capex. This represents an increase of 38.6% from the same quarter a year earlier. Against the prior quarter it is down 52.4%.
Petmed Express Inc held $13.1M in cash as of Q1 2027; long-term debt is not reported for that period.
Not reported for Q1 2027.
Margins & Returns
Petmed Express Inc's gross margin was 27.6% in Q1 2027, indicating the percentage of revenue retained after direct costs. This is down 0.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.9 percentage points.
Petmed Express Inc's operating margin was -15.2% in Q1 2027, reflecting core business profitability. This is up 51.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.9 percentage points.
Petmed Express Inc's net profit margin was -15.0% in Q1 2027, showing the share of revenue converted to profit. This is up 51.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.5 percentage points.
Petmed Express Inc's ROE was -26.7% in Q1 2027, measuring profit generated per dollar of shareholder equity. This is up 39.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 12.7 percentage points.
Capital Allocation
Petmed Express Inc invested $641K in capex in Q1 2027, funding long-term assets and infrastructure. This represents a decrease of 50.4% from the same quarter a year earlier. Against the prior quarter it is down 11.0%.
Not reported for Q1 2027.
Not reported for Q1 2027.
PETS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $41.0M-19.9% | $42.8M-15.6% | $40.7M-21.7% | $44.4M-23.6% | $51.2M-22.7% | $50.8M-22.0% | $52.0M-18.4% | $58.0M-16.4% |
| Cost of Revenue | $29.7M-19.3% | N/A | N/A | $31.9M-18.6% | $36.8M-22.0% | $35.6M-22.6% | $35.8M-19.0% | $39.3M-18.5% |
| Gross Profit | $11.3M-21.3% | $13.9M-8.3% | $9.5M-41.4% | $12.4M-33.9% | $14.4M-24.3% | $15.2M-20.4% | $16.1M-17.0% | $18.8M-11.7% |
| SG&A Expenses | $11.2M-13.5% | $11.4M-8.6% | $12.2M+13.1% | $14.2M+35.1% | $12.9M+165.7% | $12.5M-11.7% | $10.8M-19.7% | $10.5M-12.3% |
| Operating Income | -$6.2M+81.7% | -$5.7M+5.4% | -$10.5M-2226.4% | -$8.4M-1612.6% | -$34.1M-878.2% | -$6.0M-57.0% | -$450K+85.4% | $554K-36.7% |
| EBITDA | -$4.1M+87.2% | -$3.3M+17.3% | -$8.1M-810.4% | -$6.1M-375.9% | -$31.8M-621.5% | -$3.9M-103.4% | $1.1M+187.1% | $2.2M-14.5% |
| Interest Expense | $400K-20.0% | N/A | $400K0.0% | $326K | $500K | N/A | $400K | N/A |
| Income Tax | $13K+44.4% | -$102K-101.8% | $11K-97.6% | $9K+100.6% | $9K-99.1% | $5.7M+268.6% | $465K+175.2% | -$1.4M-348.0% |
| Net Income | -$6.1M+82.0% | -$4.1M+65.1% | -$10.6M-1392.6% | -$8.5M-466.3% | -$34.2M-1009.7% | -$11.6M-132.3% | -$707K+65.1% | $2.3M+225.3% |
| EPS (Basic) | -$0.28+83.0% | -$0.19+66.1% | -$0.50-1566.7% | -$0.41-472.7% | -$1.65-1016.7% | -$0.56-124.0% | -$0.03+70.0% | $0.11+175.0% |
| EPS (Diluted) | -$0.28+83.0% | -$0.19+66.1% | -$0.50-1566.7% | -$0.41-472.7% | -$1.65-1016.7% | -$0.56-124.0% | -$0.03+70.0% | $0.11+266.7% |
| Diluted Shares (Avg) | 22M+4.5% | N/A | 21M+1.8% | 21M-0.2% | 21M-0.9% | N/A | 21M+1.0% | 21M+0.8% |
Not reported in any period shown, so not listed: R&D Expenses.
PETS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $63.8M-41.9% | $81.2M-45.4% | $88.0M-39.2% | $100.3M-31.3% | $109.8M-28.1% | $148.7M-12.5% | $144.8M-16.5% | $146.0M-10.2% |
| Current Assets | $27.6M-59.3% | $43.6M-44.8% | $48.5M-29.1% | $59.5M-16.0% | $67.9M-12.5% | $78.9M-15.8% | $68.4M-28.4% | $70.8M-16.4% |
| Cash & Equivalents | $13.1M-68.2% | $21.4M-60.9% | $26.9M-46.3% | $36.1M-30.6% | $41.1M-10.6% | $54.7M-1.0% | $50.1M+1.3% | $52.0M-2.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $8.5M-53.9% | $13.6M-16.0% | $12.2M+3.5% | $14.8M+12.8% | $18.4M-28.1% | $16.2M-43.3% | $11.8M-65.9% | $13.1M-30.7% |
| Accounts Receivable | $1.7M+6.3% | $1.9M-17.7% | $1.6M-31.0% | $2.0M+21.3% | $1.6M-29.0% | $2.3M-29.4% | $2.3M+17.0% | $1.6M-25.5% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | N/A | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $26.7M0.0% | $26.7M0.0% | $26.7M0.0% |
| Total Liabilities | $40.8M-30.1% | $52.3M-17.8% | $55.2M+13.6% | $57.2M+15.4% | $58.3M-1.5% | $63.6M-13.1% | $48.6M-33.7% | $49.6M-20.4% |
| Current Liabilities | $40.6M-29.5% | $52.0M-17.1% | $54.8M+14.2% | $56.7M+16.1% | $57.6M-1.2% | $62.8M-13.0% | $48.0M-33.8% | $48.8M-20.3% |
| Non-Current Liabilities | $175K-74.2% | $217K-72.8% | $430K-34.0% | $554K-27.9% | $677K-23.3% | $798K-19.8% | $652K-26.7% | $768K-28.9% |
| Total Equity | $23.0M-55.4% | $28.9M-66.0% | $32.8M-65.9% | $43.1M-55.3% | $51.5M-44.9% | $85.1M-12.0% | $96.2M-3.9% | $96.4M-3.9% |
| Retained Earnings | $3.1M-90.4% | $9.3M-86.1% | $13.3M-83.0% | $23.9M-69.7% | $32.4M-57.7% | $66.5M-7.0% | $78.2M+2.1% | $78.9M+0.4% |
Not reported in any period shown, so not listed: Long-Term Debt.
PETS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.7M+37.4% | -$4.7M-167.7% | -$9.2M-689.5% | -$2.2M-129.4% | -$12.3M-44.1% | $7.0M-1.6% | -$1.2M+55.0% | $7.4M+1051.0% |
| Depreciation & Amortization | $2.1M-5.9% | $2.4M+17.0% | $2.4M+51.3% | $2.3M+37.4% | $2.3M+32.7% | $2.1M+9.4% | $1.6M-10.4% | $1.7M-3.2% |
| Stock-Based Compensation | $198K-66.5% | N/A | $300K-40.0% | $200K-66.7% | $591K+107.2% | N/A | $500K | $600K |
| Capital Expenditures | $641K-50.4% | $720K-69.8% | -$21K-97.3% | $2.6M+107.4% | $1.3M+89.2% | $2.4M+90.9% | $777K-30.8% | $1.3M+28.6% |
| Free Cash Flow | -$8.3M+38.6% | -$5.5M-218.2% | -$9.2M-374.8% | -$4.8M-178.3% | -$13.6M-47.4% | $4.6M-21.3% | -$1.9M+47.7% | $6.1M+447.8% |
| Investing Cash Flow | -$641K+50.4% | -$720K+69.8% | $21K+102.7% | -$2.6M-107.4% | -$1.3M-89.2% | -$2.4M-90.9% | -$777K+45.4% | -$1.3M-28.6% |
| Financing Cash Flow | -$5K+83.3% | -$38K-660.0% | $0+100.0% | -$231K-225.4% | -$30K+71.2% | -$5K+72.2% | -$1K+93.3% | -$71K+98.9% |
| Dividends Paid | $0-100.0% | -$3K-160.0% | $1K0.0% | $22K-69.0% | $1K-99.0% | $5K-72.2% | $1K-93.3% | $71K-98.9% |
Not reported in any period shown, so not listed: Share Buybacks.
PETS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 27.6%-0.5pp | 32.6%+2.6pp | 23.3%-7.8pp | 28.0%-4.4pp | 28.1%-0.6pp | 29.9%+0.6pp | 31.0%+0.5pp | 32.3%+1.7pp |
| Operating Margin | -15.2%+51.5pp | -13.3%-1.4pp | -25.8%-24.9pp | -18.9%-19.8pp | -66.7%-73.3pp | -11.9%-6.0pp | -0.9%+4.0pp | 0.9%-0.3pp |
| Net Margin | -15.0%+51.8pp | -9.5%+13.5pp | -25.9%-24.6pp | -19.2%-23.2pp | -66.7%-72.4pp | -22.9%-15.2pp | -1.4%+1.8pp | 4.0%+3.0pp |
| Return on Equity | -26.7%+39.5pp | -14.0%-0.4pp | -32.2%-31.5pp | -19.8%-22.2pp | -66.3%-70.3pp | -13.7%-8.5pp | -0.7%+1.3pp | 2.4%+1.7pp |
| Return on Assets | -9.6%+21.5pp | -5.0%+2.8pp | -12.0%-11.5pp | -8.5%-10.1pp | -31.1%-33.6pp | -7.8%-4.9pp | -0.5%+0.7pp | 1.6%+1.1pp |
| Current Ratio | 0.68-0.5x | 0.84-0.4x | 0.89-0.5x | 1.05-0.4x | 1.18-0.2x | 1.260.0x | 1.43+0.1x | 1.45+0.1x |
| Debt-to-Equity | 1.77+0.6x | 1.81+1.1x | 1.68+1.2x | 1.33+0.8x | 1.13+0.5x | 0.750.0x | 0.51-0.2x | 0.51-0.1x |
| Asset Turnover | 0.64+0.2x | 0.53+0.2x | 0.46+0.1x | 0.440.0x | 0.470.0x | 0.340.0x | 0.360.0x | 0.400.0x |
| FCF Margin | -20.3%+6.2pp | -12.8%-21.9pp | -22.7%-18.9pp | -10.8%-21.4pp | -26.5%-12.6pp | 9.1%+0.1pp | -3.7%+2.1pp | 10.5%+13.1pp |
Note: The current ratio is below 1.0 (0.84), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Petmed Express Inc PETS | FY2026 | $179.0M | -$57.3M | -32.0% | $35.8M | 26/100 |
| Wellgistics Health Inc. WGRX | FY2025 | $23.3M | -$101.3M | N/A | $8.8M | 25/100 |
| Scienture Holdings, Inc SCNX | FY2025 | $432K | -$41.5M | N/A | $14.7M | — |
| Cellyan Biotechnology Co Ltd HKPD | FY2025 | $20.3M | -$27K | -0.1% | $5.9M | 49/100 |
Where Petmed Express Inc Ranks
Frequently Asked Questions
What is Petmed Express Inc's annual revenue?
Petmed Express Inc (PETS) reported $179.0M in total revenue for fiscal year 2026. This represents a -21.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Petmed Express Inc's revenue growing?
Petmed Express Inc (PETS) revenue declined by 21.1% year-over-year, from $227.0M to $179.0M in fiscal year 2026.
Is Petmed Express Inc profitable?
No, Petmed Express Inc (PETS) reported a net income of -$57.3M in fiscal year 2026, with a net profit margin of -32.0%.
What is Petmed Express Inc's EBITDA?
Petmed Express Inc (PETS) had EBITDA of -$49.3M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Petmed Express Inc's gross margin?
Petmed Express Inc (PETS) had a gross margin of 28.1% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Petmed Express Inc's operating margin?
Petmed Express Inc (PETS) had an operating margin of -32.8% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is Petmed Express Inc's net profit margin?
Petmed Express Inc (PETS) had a net profit margin of -32.0% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is Petmed Express Inc's return on equity (ROE)?
Petmed Express Inc (PETS) has a return on equity of -198.0% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Petmed Express Inc's free cash flow?
Petmed Express Inc (PETS) recorded an outflow of $33.0M in free cash flow during fiscal year 2026. This represents a -8256.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Petmed Express Inc's operating cash flow?
Petmed Express Inc (PETS) recorded an outflow of $28.4M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Petmed Express Inc's total assets?
Petmed Express Inc (PETS) had $81.2M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Petmed Express Inc's capital expenditures?
Petmed Express Inc (PETS) invested $4.6M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
What is Petmed Express Inc's current ratio?
Petmed Express Inc (PETS) had a current ratio of 0.84 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.
What is Petmed Express Inc's debt-to-equity ratio?
Petmed Express Inc (PETS) had a debt-to-equity ratio of 1.81 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Petmed Express Inc's return on assets (ROA)?
Petmed Express Inc (PETS) had a return on assets of -70.6% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Petmed Express Inc's P/E ratio?
Petmed Express Inc (PETS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $35.8M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Petmed Express Inc's price-to-sales ratio?
Petmed Express Inc (PETS) trades at 0.2x sales, its market capitalization divided by revenue of $168.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $35.8M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Petmed Express Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, Petmed Express Inc (PETS) held $21.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $28.4M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Petmed Express Inc's Altman Z-Score?
Petmed Express Inc (PETS) has an Altman Z-Score of 0.27, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Petmed Express Inc's Piotroski F-Score?
Petmed Express Inc (PETS) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Petmed Express Inc's earnings high quality?
Petmed Express Inc (PETS) reported a net loss of $57.3M while operations used $28.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Petmed Express Inc?
Petmed Express Inc (PETS) scores 26 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.